A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Amgen
Amgen
Pfizer
National and Kapodistrian University of Athens
Boehringer Ingelheim
Servier
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Pfizer
Janssen Research & Development, LLC
Novartis
Kura Oncology, Inc.
Pfizer
Pfizer
AstraZeneca
Takeda
National University of Malaysia
Bristol-Myers Squibb
Washington University School of Medicine
Blueprint Medicines Corporation
Dizal Pharmaceuticals
Astellas Pharma Inc
Astellas Pharma Inc
Centro di Riferimento Oncologico - Aviano
Beijing Tiantan Hospital
Genentech, Inc.
Bayer
Mirati Therapeutics Inc.
National Cancer Institute, Egypt
AstraZeneca
Zhejiang Cancer Hospital
Nanfang Hospital, Southern Medical University
AstraZeneca
Jiangsu HengRui Medicine Co., Ltd.
Trinity Health Michigan
The Netherlands Cancer Institute
Brooke Army Medical Center
Takeda
National Cancer Institute, Egypt
Eli Lilly and Company
Eli Lilly and Company
Exscientia AI Limited
Eli Lilly and Company
Bayer
Daiichi Sankyo
Amgen
Novartis
Novartis
Eli Lilly and Company
Eli Lilly and Company
Eye & ENT Hospital of Fudan University